CME 2
Oncology & Theranostics Committee
Sunday, October 13, 11:30-13:00

Session Title
NET - PRRT and More

Chairpersons
Irene Virgolini (Innsbruck, Austria)
Valentina Ambrosini (Bologna, Italy)

Programme
11:30 - 11:50 David Taïeb (Marseille, France): PET/CT Imaging of PPGL in the Era of Genomic Disease Characterization (EANM/SNMMI 2019 Guidelines)
11:50 - 12:10 Michael Gabriel (Linz, Austria): Long-Term Outcome of PRRT and Predictors of Outcome
12:10 - 12:35 Alexander Haug (Vienna, Austria): PRRT - Individualized Dosimetry vs. Fixed Dose Scheme
12:35 - 13:00 Rodney Hicks (Melbourne, Australia): PRRT Treatment Sequencing and Combinations

Educational Objectives
1. To recognize the interaction of molecular imaging and genomic based on the example PPGL and to guide nuclear physicians towards appropriate use of PET tracers across PPGL subtypes
2. To know the basics and predicting factors of the long-term outcome of PRRT
3. Identify suitable treatment regimes, taking into account individualized approaches, optimizing the impact of PRRT

Summary:
This CME should give an overview on diagnosis of PPGL as based on EANM/SNMMI 2019 guidelines indicating the interaction of molecular imaging and genomic. As PRRT has become an asset in the management of NEN data on the long-term outcome are presented with special considerations on influencing factors. There is also a debate about the need of individualized dosimetry since there is no evidence that this procedure has an impact on overall survival. In clinical practice, however, we are more and confronted with complex situations, e.g. tumour progression after initial response or patients with poorly-differentiated tumours, which requires alternative approaches, e.g. combination with other modalities.

Key Words
Theranostic, NEN, PRRT, individualized therapy approaches, long-term outcome